Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study

References

• Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155–3165. doi:10.1681/ASN.2016121344
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–978. doi:10.1080/03007995.2018.1433141
   PubMed Web of Science ®Google Scholar
• Nilsson E, Gasparini A, Ärnlöv J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277–284. doi:10.1016/j.ijcard.2017.07.035
   PubMed Web of Science ®Google Scholar
• Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020;36(8):1333–1341. doi:10.1080/03007995.2020.1775072
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations. Kidney Int Rep. 2020;5(8):1280–1290. doi:10.1016/j.ekir.2020.06.004
   PubMed Web of Science ®Google Scholar
• Dashputre AA, Gatwood J, Sumida K, et al. Association of dyskalemias with short-term health care utilization in patients with advanced CKD. J Manag Care Spec Pharm. 2021;27(10):1403–1415. doi:10.18553/jmcp.2021.27.10.1403
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–393. doi:10.1016/j.ekir.2017.11.003
   PubMed Web of Science ®Google Scholar
• Sharma A, Alvarez PJ, Woods SD, Fogli J, Dai D. Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population. J Pharm Health Serv Res. 2021;12(1):35–41. doi:10.1093/jphsr/rmaa004
   Google Scholar
• Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744–762. doi:10.1016/j.mayocp.2020.06.014
   PubMed Web of Science ®Google Scholar
• Clase CM, Carrero J-J, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42–61. doi:10.1016/j.kint.2019.09.018
   PubMed Web of Science ®Google Scholar
• Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212–S220.
   PubMed Web of Science ®Google Scholar
• Johnson M, Morrison FJ, McMahon G, Su M, Turchin A. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. Am Heart J. 2023;258:49–59. doi:10.1016/j.ahj.2023.01.002
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876–e894. doi:10.1161/CIR.0000000000001062
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3 Suppl):S1–S87. doi:10.1016/j.kint.2020.11.003
   PubMedGoogle Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5 Suppl):S1–S127. doi:10.1016/j.kint.2022.06.008
   PubMed Web of Science ®Google Scholar
• Shrestha DB, Budhathoki P, Sedhai YR, et al. Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2021;95:100635. doi:10.1016/j.curtheres.2021.100635
   PubMed Web of Science ®Google Scholar
• Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020;35(9):1518–1526. doi:10.1093/ndt/gfz150
   PubMed Web of Science ®Google Scholar
• Rahman S, Marathi R. Sodium polystyrene sulfonate. In: StatPearls [Internet]. Treasure Island (FL): StatsPearls Publishing; Updated July 4, 2022.
   Google Scholar
• Desai NR, Alvarez PJ, Golestaneh L, Woods SD, Coca SG, Rowan CG. Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. J Med Econ. 2021;24(1):1025–1036. doi:10.1080/13696998.2021.1965389
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr, Agiro A, Mu F, et al. Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the RECOGNIZE I study. Expert Rev Pharmacoecon Outcomes Res. 2023;23(2):241–250. doi:10.1080/14737167.2023.2161514
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Gosmanova EO, Woods SD, et al. Real-world management of hyperkalemia with patiromer among United States veterans. Postgrad Med. 2020;132(2):176–183. doi:10.1080/00325481.2019.1706920
   PubMed Web of Science ®Google Scholar
• Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473–480. doi:10.1159/000504078
   PubMed Web of Science ®Google Scholar
• Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month Phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798–809. doi:10.2215/CJN.12651018
   PubMed Web of Science ®Google Scholar
• Agiro A, Amin A, Mu F, et al. Real-world RAAS inhibitor use and its predictors among patients initiating sodium zirconium cyclosylicate. Abstract PO1133 presented at: American Society of Nephrology (ASN) Kidney Week; November 2–7, 2021; Virtual.
   Google Scholar
• Agiro A, Amin A, Mu F, et al. Real-world use of renin-angiotensin-aldosterone system inhibitors in patients with heart failure and hypertension initiating sodium zirconium cyclosilicate: the OPTIMIZE study [abstract]. Circulation. 2021;144(Suppl 1):Abstract 10620. doi:10.1161/circ.144.suppl_1.10620
   Google Scholar
• Dai D, Sharma A, Alvarez PJ, Woods SD. Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: a retrospective observational cohort study using association rule mining. J Multimorb Comorb. 2022;12:26335565221098832. doi:10.1177/26335565221098832
   Google Scholar